drugset
drugset / Trial / NCT05343819

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.

NCT05343819 ↗

Phase 1 Completed 16 enrolled Aptarion Biotech AG
RandomizedSequentialQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic parameters after multiple ascending intravenous doses of AON-D21 in healthy male subjects.

Timeline

Start
2022-04-12
Primary completion
2022-11-29
Completion
2022-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject AON-D21 Aptamer — Intravenous

Indications

No indication recorded.